Add free shipping to your order with these great books
Theory of Drug Development : Chapman & Hall/CRC Biostatistics Series - Eric B. Holmgren
eTextbook alternate format product

Instant online reading.
Don't wait for delivery!

Go digital and save!

Theory of Drug Development

By: Eric B. Holmgren

Hardcover | 24 October 2013 | Edition Number 1

At a Glance

Hardcover


$304.40

or 4 interest-free payments of $76.10 with

 or 

Aims to ship in 15 to 25 business days

When will this arrive by?
Enter delivery postcode to estimate

Theory of Drug Development presents a formal quantitative framework for understanding drug development that goes beyond simply describing the properties of the statistics in individual studies. It examines the drug development process from the perspectives of drug companies and regulatory agencies.

By quantifying various ideas underlying drug development, the book shows how to systematically address problems, such as:

  • Sizing a phase 2 trial and choosing the range of p-values that will trigger a follow-up phase 3 trial
  • Deciding whether a drug should receive marketing approval based on its phase 2/3 development program and recent experience with other drugs in the same clinical area
  • Determining the impact of adaptive designs on the quality of drugs that receive marketing approval
  • Designing a phase 3 pivotal study that permits the data-driven adjustment of the treatment effect estimate
  • Knowing when enough information has been gathered to show that a drug improves the survival time for the whole patient population

Drawing on his extensive work as a statistician in the pharmaceutical industry, the author focuses on the efficient development of drugs and the quantification of evidence in drug development. He provides a rationale for underpowered phase 2 trials based on the notion of efficiency, which leads to the identification of an admissible family of phase 2 designs. He also develops a framework for evaluating the strength of evidence generated by clinical trials. This approach is based on the ratio of power to type 1 error and transcends typical Bayesian and frequentist statistical analyses.

Industry Reviews

"'In each chapter, author provides appropriate statistical formulas that readers can actually utilize. Since this book handles many mathematical formulas, and contains many real good examples, this book would be very useful for statisticians who work at pharmaceutical companies and are deeply involved with drug development ... Overall, this book covers necessary and important aspects for drug development, and would be quite useful to clinical statisticians."'
-Byung-Ho Nam, PhD, Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Korea, in Biometrics

"The given book presents a theory of drug development that is based on maximizing the efficiency with which drugs that truly provide clinical benefits are identified. The author shows how to optimize the drug development process at its three main stages (Phases 1, 2, 3), and at some transitional sub-stages, so that the number of molecules that result in a positive final Phase 3 clinical trial per investment is maximized."
-Fatima T. Adylova in Zentralblatt MATH


"'In each chapter, author provides appropriate statistical formulas that readers can actually utilize. Since this book handles many mathematical formulas, and contains many real good examples, this book would be very useful for statisticians who work at pharmaceutical companies and are deeply involved with drug development ... Overall, this book covers necessary and important aspects for drug development, and would be quite useful to clinical statisticians."'
-Byung-Ho Nam, PhD, Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Korea, in Biometrics

"The given book presents a theory of drug development that is based on maximizing the efficiency with which drugs that truly provide clinical benefits are identified. The author shows how to optimize the drug development process at its three main stages (Phases 1, 2, 3), and at some transitional sub-stages, so that the number of molecules that result in a positive final Phase 3 clinical trial per investment is maximized."
-Fatima T. Adylova in Zentralblatt MATH

More in Clinical Trials

Oxford Handbook of Medical Statistics : 2nd Edition - Janet L. Peacock
An Introduction to Clinical Research : Success in Medicine - Piers Page
Randomistas : How Radical Researchers Changed Our World - Andrew Leigh
Power and Sample Size in R : Chapman & Hall/CRC Biostatistics Series - Catherine M. Crespi
Handbook of Drug Screening : Drugs and the Pharmaceutical Sciences - Litao  Zhang
Veterinary Clinical Trials From Concept to Completion - Nigel Dent
Clinical Studies Management : A Practical Guide to Success - Simon  Cook
A Practical Guide to Human Research and Clinical Trials - M. U. R. Naidu